May 19, 2017
Envision Pharma Group presented original research at ISPOR in Boston, May 20–24
Envision Pharma Group presented original research at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – Sheraton Boston Hotel and the John B. Hynes Veterans Memorial Convention Center, Boston, MA, USA, May 20−24, 2017.
Members of Envision’s Market Access Solutions team and their co-authors presented new insights on the important issue of biosimilar uptake and use in the USA. Both presentations took place in Research Poster Presentations – Session II was on Monday, May 22nd (3:45-7:45pm), with an Author Discussion Hour between 6:45pm and 7:45pm.
Envision’s Karen Smoyer, PhD and Bríain Ó Hartaigh, PhD presented research on the “Uptake of the First US Biosimilar: Filgrastim-sndz Utilization Observed in a Medical Transcription Database of Patient Office Visits”.
Envision’s Karen Smoyer, PhD and Trevor Fitzpatrick, CMPP presented research conducted in collaboration with Cardinal Health on the “Initial Uptake and Utilization Patterns of Filgrastim-sndz, the First US Biosimilar”.
Events were followed in Boston on Twitter using #ISPORBoston
To contact representatives from the newly-combined Envision and Curo team, where we'll be building bridges between Evidence and Value with our range of Market Access and HEOR platforms and other technology solutions, contact Envision’s Trevor Fitzpatrick or Karen Smoyer, or Curo’s Chris O’Neill.